AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33218555 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy and rehabilitation (PTR) only (PTR group)
Number of subjects: 18
Study 34963346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention focused on enhancing the quality of the nutrition environment, self‐efficacy, and practices
Number of subjects: 0
Study 34963346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention focused on improving providers' environmental health literacy, self‐efficacy, and practices
Number of subjects: 0
Study 34650305 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid silicon stamp
Number of subjects: 54
Study 34650305 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent silicon stamp
Number of subjects: 54
Study 34650305 — intervention group
Group type: COMPARATOR
Intervention: Control group (indirect CAD/CAM composite resin restoration)
Number of subjects: 54
Study 34650305 — intervention group
Group type: EXPERIMENTAL
Intervention: General composite resin (2 mm occlusal veneer)
Number of subjects: 54
Study 35796739 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist regimen
Number of subjects: 192
Study 35796739 — intervention group
Group type: COMPARATOR
Intervention: Short GnRH agonist regimen
Number of subjects: 192
Study 33127531 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 854
Study 33127531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 854
Study 33127531 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI Stage 1
Number of subjects: 854
Study 33127531 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI Stage 2
Number of subjects: 854
Study 33127531 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI Stage 3
Number of subjects: 854
Study 35298917 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (0.5-1.0 μg/kg bodyweight, orally once daily until the end of pregnancy)
Number of subjects: 187
Study 35298917 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally once daily until the end of pregnancy)
Number of subjects: 187
Study 35298917 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 187
Study 35298917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 32485325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy liaison with training in motivational interviewing and as a patient navigator who systematically screens for health‐related social needs and provides targeted navigation services.
Number of subjects: 0
Study 32485325 — intervention group
Group type: COMPARATOR
Intervention: Usual care (pharmacy liaison to promote medication adherence).
Number of subjects: 0
Study 34728000 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient profiling tax condition based on Nutri‐Score
Number of subjects: 394
Study 34728000 — intervention group
Group type: EXPERIMENTAL
Intervention: SSB tax condition
Number of subjects: 394
Study 34728000 — intervention group
Group type: COMPARATOR
Intervention: Control condition with regular food prices
Number of subjects: 394
Study 32910097 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 1
Study 36006011 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 297
Study 36006011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 36006011 — intervention group
Group type: COMPARATOR
Intervention: Filgotinib vs. intravenous vedolizumab
Number of subjects: 297
Study 36006011 — intervention group
Group type: COMPARATOR
Intervention: Filgotinib vs. subcutaneous vedolizumab
Number of subjects: 297
Study 36006011 — intervention group
Group type: COMPARATOR
Intervention: Filgotinib vs. tofacitinib
Number of subjects: 297
Study 34308834 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg generic solifenacin succinate tablet
Number of subjects: 56
Study 34308834 — intervention group
Group type: COMPARATOR
Intervention: 5 mg solifenacin succinate tablets (vesicare)
Number of subjects: 56
Study 33412065 — intervention group
Group type: EXPERIMENTAL
Intervention: New two-qubit gate scheme using fixed-frequency qubits and a tunable coupler; controlled-Z gate produced in 30 ns with a high fidelity of 99.5%.
Number of subjects: 0
Study 33412065 — intervention group
Group type: EXPERIMENTAL
Intervention: Error analysis of the gate scheme; coherence limited errors identified.
Number of subjects: 0
Study 35046058 — intervention group
Group type: EXPERIMENTAL
Intervention: venetoclax + azacitidine
Number of subjects: 109
Study 35046058 — intervention group
Group type: COMPARATOR
Intervention: azacitidine
Number of subjects: 109
Study 34472130 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of cigarettes per day
Number of subjects: 12308
Study 34472130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime smoking index
Number of subjects: 12308
Study 34472130 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinks per week
Number of subjects: 12308
Study 34116741 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirty‐minute, self‐paced online training in English or Spanish with ongoing technical assistance
Number of subjects: 0
Study 34116741 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirty‐minute, self‐paced online training in English or Spanish without ongoing technical assistance
Number of subjects: 0
Study 34116741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study 35532908 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin (50 mg, intramuscular injection, twice weekly for 16 weeks)
Number of subjects: 130
Study 35532908 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular injection, twice weekly for 16 weeks)
Number of subjects: 130
Study 32556769 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP (Group 1)
Number of subjects: 121
Study 32556769 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP (Group 2)
Number of subjects: 121
Study 32556769 — intervention group
Group type: EXPERIMENTAL
Intervention: OMH (Group 3)
Number of subjects: 121
Study 34588198 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inhaled corticosteroids (VDKA trial)
Number of subjects: 98
Study 34588198 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective study of Puerto Rican youth
Number of subjects: 98
Study 35933275 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4) co-administered with the first dose of CoronaVac (C1 subgroup)
Number of subjects: 480
Study 35933275 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4) co-administered with the second dose of CoronaVac (C2 subgroup)
Number of subjects: 480
Study 35933275 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac administered 14 days after the first dose (S group)
Number of subjects: 480
Study 35933275 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of immune response
Number of subjects: 480
Study 33453450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 2444
Study 33453450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly (qw)
Number of subjects: 2444
Study 33453450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2444
Study 33453450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (both q2w and qw)
Number of subjects: 2444
Study 32044425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-relieved cluster (46.72% in NHRs, 11.71% in home care)
Number of subjects: 342
Study 32044425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-impaired cluster (22.63% in NHRs, 33.66% in home care)
Number of subjects: 342
Study 32044425 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pain cluster (30.66% in NHRs, 54.63% in home care)
Number of subjects: 342
Study 35006245 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 97
Study 32122177 — intervention group
Group type: EXPERIMENTAL
Intervention: WCDSAMCC
Number of subjects: 200
Study 32122177 — intervention group
Group type: COMPARATOR
Intervention: SAS
Number of subjects: 200
Study 32122177 — intervention group
Group type: COMPARATOR
Intervention: BS
Number of subjects: 200
Study 32122177 — intervention group
Group type: EXPERIMENTAL
Intervention: Other hair cleansing conditioners
Number of subjects: 200
Study 34890060 — intervention group
Group type: EXPERIMENTAL
Intervention: Previsit Decision Aid (DA)
Number of subjects: 158
Study 34890060 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-visit Decision Aid (DA)
Number of subjects: 158
Study 34890060 — intervention group
Group type: EXPERIMENTAL
Intervention: Previsit + Within-visit Decision Aid (DA)
Number of subjects: 158
Study 34890060 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 158
Study 33800559 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block (QLB)
Number of subjects: 105
Study 33800559 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block (TAPB)
Number of subjects: 105
Study 33800559 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 105
Study 32598699 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bacterial lysate (MBL) added to conventional therapy for COPD, 3 cycles of 10 days therapy with 20-day intervals between them.
Number of subjects: 60
Study 32598699 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for COPD without MBL (control group).
Number of subjects: 60
Study 34379277 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal strategies including clinician hypertension group‐based trainings, monthly clinician feedback reports, and monthly meetings with practice champions
Number of subjects: 4277
Study 34379277 — intervention group
Group type: COMPARATOR
Intervention: Control periods
Number of subjects: 4277
Study 34379277 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal strategies
Number of subjects: 4277
Study 33797058 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized single-case intervention designs
Number of subjects: 0
Study 33011586 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepractice
Number of subjects: 20
Study 33011586 — intervention group
Group type: COMPARATOR
Intervention: In-person therapy
Number of subjects: 20
Study 35213754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumen-protected lysine (RPL) supplementation (80g daily from Day 21 before expected calving to parturition)
Number of subjects: 40
Study 35213754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RPL supplementation)
Number of subjects: 40
Study 35213754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumen-protected lysine (RPL) supplementation
Number of subjects: 40
Study 33641259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics guided treatment (n=105)
Number of subjects: 213
Study 33641259 — intervention group
Group type: COMPARATOR
Intervention: Standard antidepressant treatment (n=108)
Number of subjects: 213
Study 33641259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 213
Study 33962901 — intervention group
Group type: EXPERIMENTAL
Intervention: Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition indicators for the diagnosis of adult and pediatric malnutrition
Number of subjects: 1200
Study 33962901 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis measurement
Number of subjects: 1200
Study 33962901 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered dietitian nutritionist care
Number of subjects: 1200
Study 33962901 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional nutrition care and medical outcomes (eg, mortality and length of stay)
Number of subjects: 1200
Study 33212440 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week self-guided, online cognitive behavioural intervention targeting dysfunctional COVID-19 worry and associated symptoms
Number of subjects: 670
Study 33212440 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 670
Study 36191334 — intervention group
Group type: EXPERIMENTAL
Intervention: Any analgesic administration
Number of subjects: 32463
Study 36191334 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic administration in African American patients
Number of subjects: 32463
Study 36191334 — intervention group
Group type: COMPARATOR
Intervention: Analgesic administration in White patients
Number of subjects: 32463
Study 36191334 — intervention group
Group type: COMPARATOR
Intervention: Analgesic administration in Hispanic patients
Number of subjects: 32463
Study 36191334 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of nontreatment of pain for African American patients compared to White patients
Number of subjects: 32463
Study 36191334 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of nontreatment of pain for female patients compared to male patients
Number of subjects: 32463
Study 34001002 — intervention group
Group type: EXPERIMENTAL
Intervention: M207 3.8 mg (intracutaneous zolmitriptan)
Number of subjects: 335
Study 32329160 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 468
Study 35777122 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/day of vitamin D3 supplementation
Number of subjects: 116
Study 35777122 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day of vitamin D3 supplementation
Number of subjects: 116
Study 35777122 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU/day of vitamin D3 supplementation
Number of subjects: 116
Study 33621762 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic butterfly cartilage myringoplasty
Number of subjects: 50
Study 33621762 — intervention group
Group type: COMPARATOR
Intervention: Microscopic butterfly cartilage myringoplasty
Number of subjects: 50
Study 33068185 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk plaque MRI-based model (HRPMM) using radiomics features and machine learning
Number of subjects: 162
Study 33068185 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model using both traditional and radiomics features
Number of subjects: 162
Study 33068185 — intervention group
Group type: COMPARATOR
Intervention: Traditional model based on intraplaque hemorrhage and lipid-rich necrotic core
Number of subjects: 162
Study 32412986 — intervention group
Group type: EXPERIMENTAL
Intervention: TFP block with 20 ml of 0.25% bupivacaine
Number of subjects: 60
Study 32412986 — intervention group
Group type: COMPARATOR
Intervention: Saline bilaterally
Number of subjects: 60
Study 36165603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives
Number of subjects: 340
Study 36165603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 36165603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives and menstrual cycle phases
Number of subjects: 340
Study 33586212 — intervention group
Group type: EXPERIMENTAL
Intervention: Random coefficient regression models with possible missing data and variable follow-up
Number of subjects: 0
Study 33586212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size and study design planning using data from ADNI
Number of subjects: 0
Study 33586212 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination of drivers of variability
Number of subjects: 0
Study 32554736 — intervention group
Group type: EXPERIMENTAL
Intervention: reverse TAP stenting
Number of subjects: 50
Study 32554736 — intervention group
Group type: COMPARATOR
Intervention: DK-crush stenting
Number of subjects: 50
Study 35798511 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 104
Study 35798511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 35373947 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted pelvic floor muscle training (PFMT)
Number of subjects: 68
Study 35373947 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) alone
Number of subjects: 68
Study 32019814 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 µg of vitamin B12 daily for 6 months
Number of subjects: 791
Study 32019814 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of folic acid daily for 6 months
Number of subjects: 791
Study 32019814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin B12 and folic acid daily for 6 months
Number of subjects: 791
Study 32019814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 791
Study 33524593 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-volume plasma exchange (SVPE), mean sessions 2.15 ± 1.42, median plasma volume replaced 5.049 L
Number of subjects: 40
Study 33524593 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (SMT)
Number of subjects: 40
Study 33079901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-Lock Bone-Preservation Stem
Number of subjects: 86
Study 33079901 — intervention group
Group type: COMPARATOR
Intervention: Corail prosthesis
Number of subjects: 86
Study 32916273 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal caffeine use during pregnancy
Number of subjects: 1202
Study 32916273 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin use during pregnancy
Number of subjects: 1202
Study 35986323 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (6.75 mg bolus intravenously 30 min before embryo transfer)
Number of subjects: 194
Study 35986323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline infusion)
Number of subjects: 194
Study 35986323 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 194
Study 35986323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 33887486 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologically evaluated pancreatic fibrosis
Number of subjects: 261
Study 33887486 — intervention group
Group type: COMPARATOR
Intervention: Surgically evaluated pancreatic texture
Number of subjects: 261
Study 33887486 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fibrosis grade and pancreatic texture
Number of subjects: 261
Study 32843005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (workshops and interviews to reduce physical and psychosocial load)
Number of subjects: 450
Study 32843005 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 450
Study 34958809 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Gy single session LDRT along with standard pharmacologic therapy
Number of subjects: 51
Study 34958809 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacologic therapy alone
Number of subjects: 51
Study 33684595 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of meropenem 3 g/24 h
Number of subjects: 600
Study 33684595 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of meropenem 1 g q8h
Number of subjects: 600
Study 34582678 — intervention group
Group type: EXPERIMENTAL
Intervention: OVCCA web application for health literacy promotion (6 weeks)
Number of subjects: 126
Study 34582678 — intervention group
Group type: COMPARATOR
Intervention: Control group received an activity package from the public health department
Number of subjects: 126
Study 32334033 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated WBI of 4256 cGy in 16 fractions over 22 days
Number of subjects: 1152
Study 32334033 — intervention group
Group type: COMPARATOR
Intervention: Conventional WBI of 5000 cGy in 25 fractions over 35 days
Number of subjects: 1152
Study 34583887 — intervention group
Group type: EXPERIMENTAL
Intervention: Online course on healthy diet
Number of subjects: 37
Study 34583887 — intervention group
Group type: EXPERIMENTAL
Intervention: Online course on physical activity
Number of subjects: 37
Study 33278031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil in water-based moisturizing product
Number of subjects: 0
Study 33278031 — intervention group
Group type: COMPARATOR
Intervention: Untreated site
Number of subjects: 0
Study 32509290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO) treatment at 3 g/kg body weight three times daily for 10 days
Number of subjects: 212
Study 32509290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO) treatment
Number of subjects: 212
Study 32509290 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care for SAM
Number of subjects: 212
Study 35612684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (OP-PLA)
Number of subjects: 11
Study 35612684 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg-1, OP-CAF)
Number of subjects: 11
Study 35612684 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (OP-CAF)
Number of subjects: 11
Study 33658054 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with any role in decision-making
Number of subjects: 14032
Study 33658054 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with any formal education
Number of subjects: 14032
Study 33658054 — intervention group
Group type: EXPERIMENTAL
Intervention: Women participating in any paid labor
Number of subjects: 14032
Study 33658054 — intervention group
Group type: EXPERIMENTAL
Intervention: Women living in a household with another woman who uses modern contraception
Number of subjects: 14032
Study 33658054 — intervention group
Group type: COMPARATOR
Intervention: Women living between 2 and 5 km from a primary health center
Number of subjects: 14032
Study 33658054 — intervention group
Group type: COMPARATOR
Intervention: Women living between 5 and 10 km from a primary health center
Number of subjects: 14032
Study 32446323 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive disease-modifying pharmacological therapy (ARNI, β blocker, MRA, SGLT2 inhibitor)
Number of subjects: 2737
Study 35829656 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every four weeks
Number of subjects: 206
Study 34217809 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35551878 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (methylphenidate)
Number of subjects: 84
Study 35551878 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 84
Study 35551878 — intervention group
Group type: COMPARATOR
Intervention: Behaviour Management
Number of subjects: 84
Study 35551878 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 84